Search a ticker

Categories
Biotech Stocks Coronavirus Featured Investing Stocks to Watch

2 Top Coronavirus Stocks To Buy Amid Latest Vaccine Deals?

coronavirus stocks to buy

Biotech Stocks Are On The Rise Amid News From Novavax

When we hear the term coronavirus stocks, it can refer to a broad range of sectors. Depending on the context, it could be the new-economy stocks, spanning from gaming companies and online food delivery to biotech stocks. Like it or not, small-cap biotech stocks have been a popular asset class to watch this year. The biotechnology industry has been relatively quiet in recent weeks as there are no major updates thus far. But this week, biotech stocks are back on investors’ radar once again.

We have talked about how biotech stocks have been having breakouts overnight. This is more prevalent among small-cap biotech stocks. One of the biggest winners in the space is Novavax Inc (NVAX Stock Report), with a whopping 2,200% increase year to date. Shares of NVAX skyrocketed yesterday and are 32% higher at the end of the closing bell. The catalyst? The federal government will pay the vaccine maker $1.6 billion to expedite the development of a coronavirus vaccine. This is the largest deal to date from Operation Warp Speed. The latest funding sent a strong signal to investors and kept them thinking, “is this the best biotech stock to buy right now”. When the funding news was out, it sent a few small-cap biotech stocks running on Tuesday. But the question here is, can this trend continue?

Read More

Top Coronavirus Stocks To Watch Before Friday: Vaxart

Vaxart (VXRT Stock Report) is another small-cap biotech stock, and the company develops oral tablet vaccines for Covid-19. The company reported positive preclinical data for this vaccine candidate in April. However, what’s really driving VXRT stock higher in recent weeks? That was when the company’s vaccine candidate got selected by the US government’s Operation Warp Speed for funding and inclusion in a non-human primate challenge study. Vaxart’s inclusion in Operation Warp Speed was exactly the kind of publicity the small-cap biotech needed. Shares of VXRT skyrocketed almost 300% year to date.

In the meantime, the company also has potential catalysts on the way. They might be able to keep the stock’s momentum going. Vaxart expects to announce results from its collaboration with Johnson & Johnson (JNJ Stock Report) on a universal influenza vaccine soon. Shall the results be positive, VXRT stock might see another boost in their stock prices. Being the only oral vaccine platform for Covid-19 also provides several competitive advantages, including ease of use and distribution. And if it goes well, VXRT stock might fly over the roof if the company can prove its vaccine is safe and effective in neutralizing the virus.

[Read More] 3 Coronavirus Stocks To Watch Right Now; One Up Over 500% In April

Top Coronavirus Stocks To Watch Before Friday: Emergent BioSolutions

Emergent BioSolutions (EBS Stock Report) has been all over the news since the beginning of the pandemic, with a number of COVID-19-related contracts and partnerships. EBS stock is considered as one of the top biotech stocks to buy. This came after it recently appeared on a list of companies receiving the largest Covid-19 government contracts. In mid-June, the company announced a manufacturing partnership with AstraZeneca (AZN Stock Report) to produce its Covid-19 vaccine candidate, valued at approximately $87M. Shares of EBS have risen more than 60% year to date.

A few months back, Emergent BioSolutions also announced a partnership with Johnson & Johnson to provide contract development and manufacturing services to support J&J’s Covid-19 vaccine efforts. The company also signed two contract agreements with Novavax. One is to manufacture Novavax’s NanoFlu and the other to support Novavax’s Covid-19 vaccine candidate. With these reasons, there’s a great chance other vaccine makers would want to partner with EBS, considering that the company has several manufacturing sites in Baltimore. Clearly, the company’s ability to secure multiple partnerships is testimony to its strong capabilities. These make it an ideal candidate for the coronavirus play. The company stands a chance to benefit if any of its partners become the first to create a safe and effective vaccine.

By Joe Samuel

Joe Samuel is a dedicated stock market researcher and financial contributor. His love for the stock market started at a young age learning from his grandfather. Joe earned a bachelor of science degree in corporate finance and business management. After finishing college, he went the route of an entrepreneur starting numerous businesses and eventually became a financial contributor to a number of outlets including Seeking Alpha, Invesitng.com, and actively contributes to FactSet. At StockMarket.com, Joe looks for emerging stories. One of his traits is identifying new trends before they become mainstream. Whether it’s a biopharmaceutical company debuting a novel treatment or the next technology start-up developing a new platform, Joe looks to be on the cutting edge of that trend.

After years of living in New York, he made the move to Miami, Florida where he’s become an active member of the finance community. Joe has worked with early-stage companies in marketing and consulting capacities, which has given him an opportunity to see what makes companies tick. His viewpoint is that while corporate news is vital to any investment, it’s what isn’t “right in front of you” that can make a good investment great. His approach to the markets is one that aims to deliver information that might not be well-known. But through deep research and diligence, Joe has written about and been able to uncover time-sensitive information when seconds matter in the stock market today.

Joe enjoys covering several stock market sectors. These include commodities, finance, biotechnology, and technology; specifically AI & machine learning. His no-nonsense approach to the market gives readers a cut and dry view of the news that matters most and topics beginning to emerge as new trends in the stock market. He was early to the table with calls on things like the last gold rush in 2019 and has been able to identify influential events and how they could impact certain industries.

During his free time, he enjoys spending time with his family and polishing up one new stock market trends. He’s also an avid car enthusiast with a passion for classic and muscle cars.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments